MindBio Therapeutics Closes $1.1 Million Private Placement

December 12, 2025 — Leads & Copy —

MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) has completed a non-brokered private placement, raising gross proceeds of $1,100,000. The offering included the issuance of 2,070,000 AI Units at $0.40 each, totaling $828,000, and 680,000 LIFE Units at $0.40 each, totaling up to $272,000.

Each AI Unit consists of one common share and one share purchase warrant, with each warrant allowing the holder to purchase an additional common share at $0.70 until December 12, 2028, subject to accelerated expiry. Each LIFE Unit comprises one share and one-half-of-one warrant.

The company plans to use the net proceeds to further develop its prediction technologies in drug and alcohol intoxication detection and for general working capital.

In connection with the offering, MindBio paid $72,120 and issued 162,100 warrants to parties who introduced subscribers to the offering. Securities issued under the Accredited Investor Exemption are subject to resale restrictions until April 13, 2026. Shareholder approval was obtained for the offering via written consent.

Justin Hanka, Chief Executive Officer, 61 433140886, justin@mindbiotherapeutics.com

Source: MindBio Therapeutics